Our Mastery
Testimonial
- "Amazing success ratio in such uncertain market and paid service is very affordable ...Good job done by your team...keep it up guys."
-Venkat (Chennai)
Party Plot Owner - "I am trading in stock market since last 8 years; I have subscribed services from many advisory companies. Conclusion is that no one can provide 100% accuracy in this NSE market. But accuracy of intraday tips from this firm is the highest among all share tips companies" Rahul Varma (Mumbai)
Owner of an Insurance Firm - "I have taken free trial of intraday tips for 2 days and 80% call is profitable. Then I have subscribed paid membership for trading advice and now I am quite satisfied with services. Important thing is do not think more; Just trade what you are suggested" -Kevin Patel (Ahmedabad)
BDM at IT Company - "Made Good Profit in the Intraday, Jackpot Calls, F&o Tips. Overall Service is very good. Especially I like your Fast tips Sms Service & Exit Call System. Your tips have very good performance." -Manoj Arora (Delhi)
CEO of Real Estate Company
RPG Life Sciences Ltd share price today (on 3 June 2023).
We Provide Best stock tips for RPG Life Sciences Ltd. A1 Intraday Tips is accurate share tips Provider Company in India in Nse market. A1 Intraday Tips, also provide Daily Charts with Nse Share Market current price of RPG Life Sciences Ltd with today performance in nse market. Contact Us for Jackpot Stock tips.
Get Free Stock Tips for RPG Life Sciences Ltd
Live Chart - RPG Life Sciences Ltd
BSE: 532983 | NSE: RPGLIFE | ISIN: INE105J01010 Market Cap: [Rs.Cr.] 132 | Face Value: [Rs.] 8 Industry: Pharmaceuticals - Indian - Bulk Drugs & FormlnRPG Life Sciences Ltd is engaged in the development, manufacture, and marketing of bulk drugs and formulations primarily in India. The company provides active pharmaceutical ingredients and generic formulations, as well as medications for critical and chronic ailments. They also manufacture life saving drugs using biotechnology. The company is having research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. They are having TGA (Aus) and MHRA (UK) approved facilities at Thane in Maharashtra and Ankleshwar in Gujarat.
RPG Life Sciences, a part of the Rs. 17,000 crore RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the Branded Formulations, Global Generics, Synthetic and Fermentation APIs space. The company is a research based, pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients. Customer satisfaction is fundamental to the company.
RPG Life Sciences Ltd was incorporated on March 29, 2007 with the name RPG Pharmaceuticals Ltd. During the year 2007-08, as per the scheme of arrangement, the company acquired the pharmaceuticals business of Brabourne Enterprises Ltd along with all assets and liabilities pertaining to that business with effect from April 2, 2007 (the appointed date). In February 13, 2008, the name of the company was subsequently changed to RPG Life Sciences Ltd. During the year 2008-09, the company increased the production capacity of Bulk Drugs and Chemicals from 62 tonnes to 71 tonnes.
They launched an oncology drug namely Exemestane. Also, they launched new products, namely Nufex Beta, Qugyl-O & Immunotec. In June 10, 2008, the equity shares of the company were listed on BSE and NSE with effect from June 10, 2008. In July 2008, the company commenced production in the new high capacity fermenters. During the year 2009-10, the company strengthened their product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. The new products launched during the year were Demator, Sizomax, Mela, Exinia and Mofetyl S. They launched a new immunosuppressant product, Sirolimus, during the year. Also, they introduced 11 new products across several therapeutic segments. The company plans to launch six new bulk drugs and two existing products in new markets. They also plan to file DMFs for several products in regulated and semi regulated markets. The company is having plans to set up dedicated divisions with their own sales force and portfolio of brands that will drive the business in therapeutic areas like oncology, psychiatry and diabetology.
According to the Individual - Audited financial statement for the Year of 2012, total net operating revenues increased with 7.95%, from INR 177.96 tens of millions to INR 192.11 tens of millions. Operating result decreased from INR 31.98 tens of millions to INR 18.15 tens of millions which means -43.25% change. The results of the period decreased -92.99% reaching INR 0.85 tens of millions at the end of the period against INR 12.12 tens of millions last year. Return on equity (Net income/Total equity) went from 16.20% to 1.15%, the Return On Asset (Net income / Total Asset) went from 9.07% to 0.82% and the Net Profit Margin (Net Income/Net Sales) went from 6.81% to 0.44% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 69.98% compared to 80.57% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 1.37 to 1.27 when compared to the previous year.
Under one plan with Unbelievable lowest price
( Equity cash, Nse f&o tips, jackpot tips, sure shot call, nifty tips/bank nifty tips)
free trial available for 2 days
2 days free trial Available
( Equity cash, Nse f&o tips, jackpot tips, sure shot call, btst/stbt call/nifty tips/bank nifty tips)
Nse Listed Companies with Live Charts
with live charts starting with that Alphabet.)
| A | B | C | D | E | F | G | H | I | J |
| K | L | M | N | O | P | Q | R | S | T |
| U | V | W | X | Y | Z |
